Claims for Patent: 9,353,103

Summary for Patent: 9,353,103

Title:	Macrocyclic inhibitors of hepatitis C virus
Abstract:	Inhibitors of HCV replication of formula (I) and the N-oxides, salts, and stereoisomers, wherein each dashed line represents an optional double bond; X is N, CH and where X bears a double bond it is C; R1 is —OR7, —NH—SO2R8; R2 is hydrogen, and where X is C or CH, R2 may also be C1-6alkyl; R3 is hydrogen, C1-6alkyl, C1-6alkoxyC1-6alkyl, C3-7cycloalkyl; R4 is aryl or Het; n is 3, 4, 5, or 6; R5 is halo, C1-6alkyl, hydroxy, C1-6alkoxy, phenyl, or Het; R6 is C1-6alkoxy, or dimethylamino; R7 is hydrogen; aryl; Het; C3-7cycloalkyl optionally substituted with C1-6alkyl; or C1-6alkyl optionally substituted with C3-7cycloalkyl, aryl or with Het; R8 is aryl; Het; C3-7cycloalkyl optionally substituted with C1-6alkyl; or C1-6alkyl optionally substituted with C3-7cycloalkyl, aryl or with Het; aryl is phenyl optionally substituted with one, two or three substituents; Het is a 5 or 6 membered saturated, partially unsaturated or completely unsaturated heterocyclic ring containing 1 to 4 heteroatoms selected from nitrogen, oxygen and sulfur, and being optionally substituted with one, two or three substituents; pharmaceutical compositions containing compounds (I) and processes for preparing compounds (I). Bioavailable combinations of the inhibitors of HCV of formula (I) with ritonavir are also provided.
Inventor(s):	Kenneth Alan Simmen, Herman Augustinus De Kock, Pierre Jean-Marie Bernard Raboisson, Lili Hu, Abdellah Tahri, Dominique Louis Nestor Ghislain Surleraux, Karl Magnus Nilsson, Bengt Bertil Samuelsson, Asa Annica Kristina Rosenquist, Vladimir Ivanov, Mikael Pelcman, Anna Karin Gertrud Linea Belfrage, Per-Ola Mikael Johansson, Sandrine Marie Helene Vendeville
Assignee:	Janssen Sciences Ireland ULC, Medivir AB
Application Number:	US14/684,649
Patent Claims:	1. A method of treating a hepatitis C virus (HCV) infection in a patient comprising administering to the patient: a compound having the formula or a pharmaceutically acceptable salt thereof; and another anti-HCV agent. 2. The method of claim 1, comprising administering a pharmaceutically acceptable salt of the compound. 3. The method of claim 2, wherein the pharmaceutically acceptable salt is the sodium salt. 4. The method of claim 1, wherein the other anti-HCV agent is an HCV polymerase inhibitor, an HCV protease inhibitor, an inhibitor of another target in the HCV life cycle, and immunomodulatory agent, an antiviral agent, or a combination thereof. 5. The method of claim 1, wherein the other anti-HCV agent is an HCV polymerase inhibitor, an HCV protease inhibitor, an antiviral agent, or a combination thereof. 6. The method of claim 1, wherein the other anti-HCV agent is an HCV polymerase inhibitor. 7. The method of claim 1, wherein the other anti-HCV agent is an HCV protease inhibitor. 8. The method of claim 1, wherein the other anti-HCV agent is an antiviral agent. 9. The method of claim 1, wherein the other anti-HCV agent is ribavirin. 10. The method of claim 1, wherein the other anti-HCV agent is pegylated interferon-α. 11. The method of claim 1, wherein the other anti-HCV agent is ribavirin and pegylated interferon-α. 12. The method of claim 1, wherein the compound and the other anti-HCV agent are administered simultaneously. 13. The method of claim 1, wherein the compound and the other anti-HCV agent are administered separately. 14. The method of claim 1, wherein the compound and the other anti-HCV agent are administered sequentially.